Elutia is a small medical device company focused on biologic matrix products for surgical reconstruction, combining extracellular matrix scaffolds with localized sustained antibiotic drug delivery to reduce post-surgical infection and implant failure. The company is essentially a pre-revenue R&D stage business following the 2025 sale of its cardiac implantable electronic device (CIED) envelope products — EluPro and CanGaroo — to Boston Scientific for up to $88M, and the 2023 sale of its orthobiologics segment for ~$14.6M. Elutia's lead pipeline programs are NXT-41 and NXT-41x, both biologic matrices targeting breast reconstruction surgery. NXT-41 is a porcine-derived engineered biomatrix, and NXT-41x builds on NXT-41 by incorporating sustained antibiotic release over 30+ days. Elutia has submitted NXT-41 to the FDA and expects clearance in the second half of 2026, followed by NXT-41x by mid-2027. The company currently generates modest revenue from two commercial products: SimpliDerm, a human acellular dermal matrix sold to plastic surgeons through independent sales agents, and a small portfolio of cardiovascular biologic patches. Management views SimpliDerm primarily as a way to build surgeon relationships and commercial infrastructure ahead of NXT-41x's launch, and is exploring a sale of SimpliDerm. If cleared, NXT-41x would be sold as a premium biologic mesh to hospitals performing breast reconstruction, priced competitively with the existing market. Elutia holds approximately $44.4M in cash and escrow to fund development through commercialization.